Gelesis Holdings Current Ratio 2021-2022 | GLS

Gelesis Holdings current ratio from 2021 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Gelesis Holdings Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-03-31 $0.07B $0.05B 1.42
2021-12-31 $0.07B $0.10B 0.65
2021-09-30 $0.00B $0.00B 0.13
2021-06-30 $0.00B $0.00B 0.39
2021-03-31 $0.00B $0.00B 0.45
2020-12-31 $0.00B 0.00
2020-09-30 $0.00B $0.00B 19.25
2020-06-30 $0.00B $0.00B 0.15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.114B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.283B 10.36
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.670B 16.84
Biohaven Pharmaceutical Holding (BHVN) United States $10.157B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.957B 0.00
Arcus Biosciences (RCUS) United States $1.815B 46.02
Emergent Biosolutions (EBS) United States $1.640B 7.02
Myovant Sciences (MYOV) United Kingdom $1.243B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00